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There is no treatment nor vaccine
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• Serology (ELISA, LFA)
7.  FUTURE PERSPECTIVES
dsDNA virus
Family Asfarviridae
ARBOVIRUS
Icosahedral form
22 genotypes
Target cells:
MACROPHAGES
Differential diagnosis
• Classical Swine Fever
The aim of this bibliographic review is to provide an update on the current situation of African Swine
Fever (ASF) worldwide, discussing its main epidemiological and pathogenic aspects. ASF is a highly
contagious hemorrhagic disease that affects both domestic and wild pigs. This OIE-notifiable disease is
considered one of the most important transboundary illnesses in pigs. For many years ASF has
remained endemic in Sardinia and Southern Africa. However, only a few years ago it was re-introduced
in Europe once again through the Caucasus.
• Generalized hemorrhages
Fig 1. Countries where ASF is 
present (red, rose, purple). 
Fig 2. ASFV main transmission routes: sylvatic cycle, domestic cycle, 
through contaminated pork products and fomites.
Fig 3. ASFV 
morphology.
Fig 4. Macrophages 
infected with ASFV.
Fig 5. Acute petechiae in 
the kidney.
Fig 6. Positive HAD 
“rosette” test.
ASFV has an important social and economic impact in the swine industry. Its potential to rapidly spread and produce long-term
persistent infection threatens many ASF-free European and Asian countries. Up to now, stamping out policies are the only measure
able to control this disease, but they are ethically and financially difficult to accept. For this reason, the future control and
elimination of ASFV occurrence depends on the development of an effective and safe DIVA vaccine .
